

# Sandra Ciesek

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3258735/publications.pdf>

Version: 2024-02-01

160  
papers

9,256  
citations

57758

44  
h-index

54911

84  
g-index

202  
all docs

202  
docs citations

202  
times ranked

17898  
citing authors

#	ARTICLE	IF	CITATIONS
1	A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model. <i>European Journal of Immunology</i> , 2022, 52, 770-783.	2.9	24
2	COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view. <i>Journal of Molecular Medicine</i> , 2022, 100, 463-470.	3.9	8
3	Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates. <i>Cell Research</i> , 2022, 32, 319-321.	12.0	89
4	Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1132-1139.	0.7	12
5	RNA reference materials with defined viral RNA loads of SARS-CoV-2: A useful tool towards a better PCR assay harmonization. <i>PLoS ONE</i> , 2022, 17, e0262656.	2.5	29
6	Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma. <i>Blood</i> , 2022, 139, 137-142.	1.4	29
7	Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1049.	4.1	13
8	Development and optimization of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: Evaluation of 5676 Phase 1 Passed Structures. <i>Journal of Medical Virology</i> , 2022, 94, 3101-3111.	5.0	13
9	SARS-CoV-2-specific T cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID-19 vaccination. <i>European Journal of Immunology</i> , 2022, 52, 1194-1197.	2.9	9
10	SARS-CoV-2 screening strategies for returning international travellers: Evaluation of a rapid antigen test approach. <i>International Journal of Infectious Diseases</i> , 2022, 118, 126-131.	3.3	4
11	Impact of Moderna mRNA-1273 Booster Vaccine on Fully Vaccinated High-Risk Chronic Dialysis Patients after Loss of Humoral Response. <i>Vaccines</i> , 2022, 10, 585.	4.4	14
12	Low But Recoverable Markers of Humoral Immune Response to BNT162b2 in Elderly LTCF Residents Five to Seven Months After Two-Dose Vaccination. <i>Frontiers in Aging</i> , 2022, 3, .	2.6	7
13	Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 366.e1-366.e7.	1.2	10
14	Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma. <i>Cancer Cell</i> , 2022, 40, 587-589.	16.8	18
15	SARS-CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment. <i>Cell Discovery</i> , 2022, 8, 42.	6.7	22
16	Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response. , 2022, 1, .		16
17	Wastewater surveillance allows early detection of SARS-CoV-2 omicron in North Rhine-Westphalia, Germany. <i>Science of the Total Environment</i> , 2022, 846, 157375.	8.0	13
18	Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies. <i>EBioMedicine</i> , 2022, 82, 104158.	6.1	128

#	ARTICLE	IF	CITATIONS
19	Human Mesenchymal Stromal Cells Are Resistant to SARS-CoV-2 Infection under Steady-State, Inflammatory Conditions and in the Presence of SARS-CoV-2-Infected Cells. <i>Stem Cell Reports</i> , 2021, 16, 419-427.	4.8	34
20	Detection of SARS-CoV-2 in raw and treated wastewater in Germany – Suitability for COVID-19 surveillance and potential transmission risks. <i>Science of the Total Environment</i> , 2021, 751, 141750.	8.0	300
21	Evaluation of a SARS-CoV-2 rapid antigen test: Potential to help reduce community spread?. <i>Journal of Clinical Virology</i> , 2021, 135, 104713.	3.1	102
22	Calling for pan-European commitment for rapid and sustained reduction in SARS-CoV-2 infections. <i>Lancet, The</i> , 2021, 397, 92-93.	13.7	71
23	Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 2021, 223, 56-61.	4.0	65
24	Longitudinal Testing for Respiratory and Gastrointestinal Shedding of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Day Care Centers in Hesse, Germany. <i>Clinical Infectious Diseases</i> , 2021, 73, e3036-e3041.	5.8	18
25	Pediatrics and COVID-19. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1318, 197-208.	1.6	3
26	Differentially conserved amino acid positions may reflect differences in SARS-CoV-2 and SARS-CoV behaviour. <i>Bioinformatics</i> , 2021, 37, 2282-2288.	4.1	9
27	An action plan for pan-European defence against new SARS-CoV-2 variants. <i>Lancet, The</i> , 2021, 397, 469-470.	13.7	101
28	A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection. <i>Scientific Data</i> , 2021, 8, 70.	5.3	65
29	Infectivity of deceased COVID-19 patients. <i>International Journal of Legal Medicine</i> , 2021, 135, 2055-2060.	2.2	32
30	Typical symptoms of common otorhinolaryngological diseases may mask a SARS-CoV-2 infection. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 3551-3558.	1.6	2
31	Call for a pan-European COVID-19 response must be comprehensive – Authors' reply. <i>Lancet, The</i> , 2021, 397, 1541.	13.7	0
32	High-Frequency Self-Testing by Schoolteachers for Sars-Cov-2 Using a Rapid Antigen Test: Results of the Safe School Hesse study. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , 2021, 118, 252-253.	0.9	8
33	Surveillance of SARS-CoV-2 in Frankfurt am Main from October to December 2020 Reveals High Viral Diversity Including Spike Mutation N501Y in B.1.1.70 and B.1.1.7. <i>Microorganisms</i> , 2021, 9, 748.	3.6	14
34	In vitro activity of itraconazole against SARS-CoV-2. <i>Journal of Medical Virology</i> , 2021, 93, 4454-4460.	5.0	30
35	A method for the rational selection of drug repurposing candidates from multimodal knowledge harmonization. <i>Scientific Reports</i> , 2021, 11, 11049.	3.3	12
36	Comparative analysis of point-of-care, high-throughput and laboratory-developed SARS-CoV-2 nucleic acid amplification tests (NATs). <i>Journal of Virological Methods</i> , 2021, 291, 114102.	2.1	22

#	ARTICLE	IF	CITATIONS
37	Utility of Different Surrogate Enzyme-Linked Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies. <i>Journal of Clinical Medicine</i> , 2021, 10, 2128.	2.4	51
38	Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro. <i>Journal of Infectious Diseases</i> , 2021, 224, 1109-1114.	4.0	56
39	Generation of a Sleeping Beauty Transposon-Based Cellular System for Rapid and Sensitive Screening for Compounds and Cellular Factors Limiting SARS-CoV-2 Replication. <i>Frontiers in Microbiology</i> , 2021, 12, 701198.	3.5	27
40	Increased susceptibility of human endothelial cells to infections by SARS-CoV-2 variants. <i>Basic Research in Cardiology</i> , 2021, 116, 42.	5.9	33
41	Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 1498.	3.3	33
42	Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings. <i>Medical Microbiology and Immunology</i> , 2021, 210, 235-244.	4.8	37
43	Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q. <i>Viruses</i> , 2021, 13, 1693.	3.3	69
44	Characterization of ACE Inhibitors and AT1R Antagonists with Regard to Their Effect on ACE2 Expression and Infection with SARS-CoV-2 Using a Caco-2 Cell Model. <i>Life</i> , 2021, 11, 810.	2.4	9
45	Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection. <i>Journal of Biological Chemistry</i> , 2021, 297, 100925.	3.4	43
46	COVID-19 among children seeking primary paediatric care with signs of an acute infection. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2021, 110, 3315-3321.	1.5	4
47	A Potential Role of the CD47/SIRPalpha Axis in COVID-19 Pathogenesis. <i>Current Issues in Molecular Biology</i> , 2021, 43, 1212-1225.	2.4	9
48	Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: A European multicenter study. <i>Journal of Clinical Virology</i> , 2021, 142, 104932.	3.1	19
49	Powered air-purifying respirators used during the SARS-CoV-2 pandemic significantly reduce speech perception. <i>Journal of Occupational Medicine and Toxicology</i> , 2021, 16, 43.	2.2	7
50	Landscape of T-cell repertoires with public COVID-19-associated T-cell receptors in pre-pandemic risk cohorts. <i>Clinical and Translational Immunology</i> , 2021, 10, e1340.	3.8	16
51	The Comparative Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests and Their Correlation to Infectivity In Vitro. <i>Journal of Clinical Medicine</i> , 2021, 10, 328.	2.4	141
52	Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease. <i>PLoS ONE</i> , 2021, 16, e0258684.	2.5	5
53	Targeting the Pentose Phosphate Pathway for SARS-CoV-2 Therapy. <i>Metabolites</i> , 2021, 11, 699.	2.9	25
54	Self-Collected Samples to Detect SARS-CoV-2: Direct Comparison of Saliva, Tongue Swab, Nasal Swab, Chewed Cotton Pads and Gargle Lavage. <i>Journal of Clinical Medicine</i> , 2021, 10, 5751.	2.4	16

#	ARTICLE	IF	CITATIONS
55	Efficient inactivation of pseudotyped HIV-based lentiviral vectors and infectious HIV. <i>Journal of Virological Methods</i> , 2020, 276, 113768.	2.1	1
56	Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. <i>Nature</i> , 2020, 587, 657-662.	27.8	818
57	Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2 Replication. <i>Molecular Cell</i> , 2020, 80, 164-174.e4.	9.7	199
58	COVID-19-Related Coagulopathy—Is Transferrin a Missing Link?. <i>Diagnostics</i> , 2020, 10, 539.	2.6	32
59	Aprotinin Inhibits SARS-CoV-2 Replication. <i>Cells</i> , 2020, 9, 2377.	4.1	72
60	SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes. <i>Cardiovascular Research</i> , 2020, 116, 2207-2215.	3.8	189
61	48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection. <i>Journal of Hepatology</i> , 2020, 73, S52-S53.	3.7	54
62	Assessment of SARS-CoV-2 Transmission on an International Flight and Among a Tourist Group. <i>JAMA Network Open</i> , 2020, 3, e2018044.	5.9	55
63	Toll-like receptor 7 and 8 agonists as potent inhibitors of hepatitis delta virus infection. <i>Journal of Hepatology</i> , 2020, 73, S845-S846.	3.7	0
64	Dysfunctional adaptive immunity in liver cirrhosis and acute-on-chronic liver failure is characterized by aberrant immune checkpoint expression and diminished cytokine secretion in T cells. <i>Journal of Hepatology</i> , 2020, 73, S503.	3.7	0
65	<scp>SARSâ€CoV</scp>â€2 asymptomatic and symptomatic patients and risk for transfusion transmission. <i>Transfusion</i> , 2020, 60, 1119-1122.	1.6	83
66	Lack of antiviral activity of darunavir against SARS-CoV-2. <i>International Journal of Infectious Diseases</i> , 2020, 97, 7-10.	3.3	108
67	Clinical performance of different SARSâ€CoVâ€2 IgG antibody tests. <i>Journal of Medical Virology</i> , 2020, 92, 2243-2247.	5.0	119
68	Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. <i>Journal of Clinical Virology</i> , 2020, 129, 104480.	3.1	173
69	Optimized qRT-PCR Approach for the Detection of Intra- and Extra-Cellular SARS-CoV-2 RNAs. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4396.	4.1	68
70	Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease. <i>Immunity</i> , 2020, 53, 442-455.e4.	14.3	281
71	Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. <i>Nature</i> , 2020, 583, 469-472.	27.8	841
72	Novel multiple swab method enables high efficiency in <scp>SARSâ€CoV</scp>â€2 screenings without loss of sensitivity for screening of a complete population. <i>Transfusion</i> , 2020, 60, 2441-2447.	1.6	28

#	ARTICLE	IF	CITATIONS
73	Comprehensive Evaluation of Hepatitis E Serology and Molecular Testing in a Large Cohort. <i>Pathogens</i> , 2020, 9, 137.	2.8	12
74	Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. <i>New England Journal of Medicine</i> , 2020, 382, 1278-1280.	27.0	514
75	Thirty years of CMV seroprevalence—a longitudinal analysis in a German university hospital. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 1095-1102.	2.9	16
76	Ad hoc laboratory-based surveillance of SARS-CoV-2 by real-time RT-PCR using minipools of RNA prepared from routine respiratory samples. <i>Journal of Clinical Virology</i> , 2020, 127, 104381.	3.1	43
77	Sofosbuvir Activates EGFR-Dependent Pathways in Hepatoma Cells with Implications for Liver-Related Pathological Processes. <i>Cells</i> , 2020, 9, 1003.	4.1	10
78	Dysregulated Adaptive Immunity Is an Early Event in Liver Cirrhosis Preceding Acute-on-Chronic Liver Failure. <i>Frontiers in Immunology</i> , 2020, 11, 534731.	4.8	26
79	Multicentre comparison of quantitative PCR-based assays to detect SARS-CoV-2, Germany, March 2020. <i>Eurosurveillance</i> , 2020, 25, .	7.0	60
80	Automated Nucleic Acid Isolation Methods for HDV viral Load Quantification can Lead to viral Load Underestimation. <i>Antiviral Therapy</i> , 2019, 24, 117-123.	1.0	24
81	THU-049-Impaired adaptive immunity is an early event in liver cirrhosis preceding acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2019, 70, e181-e182.	3.7	0
82	Infectivity and stability of hepatitis C virus in different perfusion solutions. <i>Transplant Infectious Disease</i> , 2019, 21, e13135.	1.7	1
83	Yellow Fever: Integrating Current Knowledge with Technological Innovations to Identify Strategies for Controlling a Re-Emerging Virus. <i>Viruses</i> , 2019, 11, 960.	3.3	15
84	Clinical and Virological Aspects of HBV Reactivation: A Focus on Acute Liver Failure. <i>Viruses</i> , 2019, 11, 863.	3.3	5
85	Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells. <i>Journal of Hepatology</i> , 2019, 71, 301-312.	3.7	62
86	GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection. <i>Journal of Hepatology</i> , 2019, 70, e81.	3.7	93
87	Characterization of the Filovirus-Resistant Cell Line SH-SY5Y Reveals Redundant Role of Cell Surface Entry Factors. <i>Viruses</i> , 2019, 11, 275.	3.3	7
88	The detection of BKPyV genotypes II and IV after renal transplantation as a simple tool for risk assessment for PyVAN and transplant outcome already at early stages of BKPyV reactivation. <i>Journal of Clinical Virology</i> , 2019, 113, 14-19.	3.1	8
89	Clinical Outcome and Viral Genome Variability of Hepatitis B Virus-Induced Acute Liver Failure. <i>Hepatology</i> , 2019, 69, 993-1003.	7.3	19
90	SEC14L2, a lipid-binding protein, regulates HCV replication in culture with inter- and intra-genotype variations. <i>Journal of Hepatology</i> , 2019, 70, 603-614.	3.7	9

#	ARTICLE	IF	CITATIONS
91	Influenza virus infection as precipitating event of acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2019, 70, 797-799.	3.7	62
92	Expression Cloning of Host Factors Required for the HCV Replication Cycle. <i>Methods in Molecular Biology</i> , 2019, 1911, 169-182.	0.9	1
93	Sodium taurocholate cotransporting polypeptide variants modulate HDV entry according to their function as a bile acid transporter but do not influence the antiviral effect of Mycludex-B. <i>Journal of Hepatology</i> , 2018, 68, S781.	3.7	0
94	Clinical patterns associated with the concurrent detection of anti-HBs and HBV DNA. <i>Journal of Medical Virology</i> , 2018, 90, 282-290.	5.0	4
95	Impact of immune suppressive agents on the BK-Polyomavirus non coding control region. <i>Antiviral Research</i> , 2018, 159, 68-76.	4.1	12
96	Expanding the donor pool-decontamination of HCV RNA positive kidneys with methylene blue. <i>Journal of Hepatology</i> , 2018, 68, S764-S765.	3.7	0
97	Methylene Blue Treatment of Grafts During Cold Ischemia Time Reduces the Risk of Hepatitis C Virus Transmission. <i>Journal of Infectious Diseases</i> , 2018, 218, 1711-1721.	4.0	10
98	Environmental Stability and Infectivity of Hepatitis C Virus (HCV) in Different Human Body Fluids. <i>Frontiers in Microbiology</i> , 2018, 9, 504.	3.5	7
99	Mutations in HCV NS3 but no Sec14L2 variants alter HCV RNA replication of natural occurring viruses in cell culture. <i>Journal of Hepatology</i> , 2018, 68, S763-S764.	3.7	0
100	Role of BK polyomavirus (BKV) and Torque teno virus (TTV) in liver transplant recipients with renal impairment. <i>Journal of Medical Microbiology</i> , 2018, 67, 1496-1508.	1.8	22
101	A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection. <i>Antiviral Research</i> , 2017, 141, 116-123.	4.1	9
102	Clinical course and core variability in HBV infected patients without detectable anti-HBc antibodies. <i>Journal of Clinical Virology</i> , 2017, 93, 46-52.	3.1	13
103	Scavenger receptor class B member 1 ( SCARB1 ) variants modulate hepatitis C virus replication cycle and viral load. <i>Journal of Hepatology</i> , 2017, 67, 237-245.	3.7	26
104	A novel mid-scale screening assay to identify compounds with anti-HDV activity. <i>Journal of Hepatology</i> , 2017, 66, S258.	3.7	0
105	HBV reactivation in allogeneic stem cell transplant recipients: Risk factors, outcome, and role of hepatitis B virus mutations. <i>Hepatology Communications</i> , 2017, 1, 1014-1023.	4.3	6
106	Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators. <i>Gut</i> , 2016, 65, 1015-1023.	12.1	7
107	Prevention strategies for blood-borne viruses in the Era of vaccines, direct acting antivirals and antiretroviral therapy. <i>Reviews in Medical Virology</i> , 2016, 26, 330-339.	8.3	17
108	Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus reinfection after liver transplantation. <i>Transplant Infectious Disease</i> , 2016, 18, 326-332.	1.7	42



#	ARTICLE	IF	CITATIONS
109	Single- and multiple-dose pharmacokinetics of ethambutol and rifampicin in a tuberculosis patient with acute respiratory distress syndrome undergoing extended daily dialysis and ECMO treatment. <i>International Journal of Infectious Diseases</i> , 2016, 42, 1-3.	3.3	11
110	Host cell mTORC1 is required for HCV RNA replication. <i>Gut</i> , 2016, 65, 2017-2028.	12.1	47
111	Cationic amphiphilic drugs enhance entry of lentiviral particles pseudotyped with rabies virus glycoprotein into non-neuronal cells. <i>Antiviral Research</i> , 2015, 124, 122-131.	4.1	5
112	Genetic deficiency and polymorphisms of cyclophilin A reveal its essential role for Human Coronavirus 229E replication. <i>Current Opinion in Virology</i> , 2015, 14, 56-61.	5.4	33
113	Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015, 1, 285-294.e1.	4.5	5
114	Cyclophilin polymorphism and virus infection. <i>Current Opinion in Virology</i> , 2015, 14, 47-49.	5.4	13
115	Primary Biliary Acids Inhibit Hepatitis D Virus (HDV) Entry into Human Hepatoma Cells Expressing the Sodium-Taurocholate Cotransporting Polypeptide (NTCP). <i>PLoS ONE</i> , 2015, 10, e0117152.	2.5	24
116	The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2123-2131.	3.0	159
117	Impact of single nucleotide polymorphisms in the essential HCV entry factor CD81 on HCV infectivity and neutralization. <i>Antiviral Research</i> , 2014, 101, 37-44.	4.1	8
118	Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles. <i>Hepatology</i> , 2014, 60, 508-520.	7.3	7
119	Hepatitis C virus core antigen testing in liver and kidney transplant recipients. <i>Journal of Viral Hepatitis</i> , 2014, 21, 769-779.	2.0	25
120	Stability and transmission of hepatitis C virus in different anesthetic agents. <i>American Journal of Infection Control</i> , 2013, 41, 942-943.	2.3	3
121	Relevance of Resistance Against Direct Acting Antiviral Agents in Hepatitis C Virus Infection – What Technology do we Really Need in Clinical Practice?. <i>Current Hepatitis Reports</i> , 2013, 12, 195-199.	0.3	0
122	Characterization of the inhibition of hepatitis C virus entry by <i>in vitro</i> -generated and patient-derived oxidized low-density lipoprotein. <i>Hepatology</i> , 2013, 57, 1716-1724.	7.3	16
123	Inactivation of Hepatitis C Virus Infectivity by Human Breast Milk. <i>Journal of Infectious Diseases</i> , 2013, 208, 1943-1952.	4.0	47
124	Transmission of Hepatitis C Virus Among People Who Inject Drugs: Viral Stability and Association With Drug Preparation Equipment. <i>Journal of Infectious Diseases</i> , 2013, 207, 281-287.	4.0	57
125	Interferon- $\gamma$ -Stimulated Natural Killer Cells From Patients With Acute Hepatitis C Virus (HCV) Infection Recognize HCV-Infected and Uninfected Hepatoma Cells via DNAX accessory molecule-1. <i>Journal of Infectious Diseases</i> , 2012, 205, 1351-1362.	4.0	38
126	Hepatocytes That Express Variants of Cyclophilin A Are Resistant to HCV Infection and Replication. <i>Gastroenterology</i> , 2012, 143, 439-447.e1.	1.3	30



#	ARTICLE	IF	CITATIONS
127	Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitro. <i>Antiviral Research</i> , 2012, 96, 51-58.	4.1	2
128	Immunosuppression, liver injury and post-transplant HCV recurrence. <i>Journal of Viral Hepatitis</i> , 2012, 19, 1-8.	2.0	44
129	Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 1092-1098.	1.5	94
130	Second-wave Protease Inhibitors: Choosing an Heir. <i>Clinics in Liver Disease</i> , 2011, 15, 597-609.	2.1	27
131	772 SINGLE NUCLEOTIDE POLYMORPHISMS IN HUMAN CYCLOPHILIN A AND THEIR INFLUENCE ON HCV RNA REPLICATION IN VITRO. <i>Journal of Hepatology</i> , 2011, 54, S310-S311.	3.7	0
132	Hepatitis C virus enters human peripheral neuroblastoma cells - evidence for extra-hepatic cells sustaining hepatitis C virus penetration. <i>Journal of Viral Hepatitis</i> , 2011, 18, 562-570.	2.0	24
133	The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. <i>Hepatology</i> , 2011, 54, 1947-1955.	7.3	255
134	Impact of Intra- and Interspecies Variation of Occludin on Its Function as Coreceptor for Authentic Hepatitis C Virus Particles. <i>Journal of Virology</i> , 2011, 85, 7613-7621.	3.4	40
135	The dawn of a new era in HCV therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 69-71.	17.8	57
136	Prolonged Survival of Hepatitis C Virus in the Anesthetic Propofol. <i>Clinical Infectious Diseases</i> , 2011, 53, 963-964.	5.8	11
137	Inactivation and Survival of Hepatitis C Virus on Inanimate Surfaces. <i>Journal of Infectious Diseases</i> , 2011, 204, 1830-1838.	4.0	90
138	The Novel Immunosuppressive Protein Kinase C Inhibitor Sotrastaurin Has No Pro-Viral Effects on the Replication Cycle of Hepatitis B or C Virus. <i>PLoS ONE</i> , 2011, 6, e24142.	2.5	9
139	Arrest all accessories--inhibition of hepatitis C virus by compounds that target host factors. <i>Discovery Medicine</i> , 2011, 12, 237-44.	0.5	32
140	Anti-parietal cell autoantibodies (PCA) in primary biliary cirrhosis: a putative marker for recurrence after orthotopic liver transplantation?. <i>Annals of Hepatology</i> , 2010, 9, 181-185.	1.5	6
141	Hepatitis C Virus Hypervariable Region 1 Modulates Receptor Interactions, Conceals the CD81 Binding Site, and Protects Conserved Neutralizing Epitopes. <i>Journal of Virology</i> , 2010, 84, 5751-5763.	3.4	201
142	Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 63-79.	3.0	8
143	How Stable Is the Hepatitis C Virus (HCV)? Environmental Stability of HCV and Its Susceptibility to Chemical Biocides. <i>Journal of Infectious Diseases</i> , 2010, 201, 1859-1866.	4.0	72
144	Membranous Budd-Chiari syndrome in Caucasians. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 226-234.	1.5	19

#	ARTICLE	IF	CITATIONS
145	Glucocorticosteroids Increase Cell Entry by Hepatitis C Virus. <i>Gastroenterology</i> , 2010, 138, 1875-1884.	1.3	68
146	Interferon- $\gamma$ -Induced TRAIL on Natural Killer Cells Is Associated With Control of Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2010, 138, 1885-1897.e10.	1.3	177
147	Anti-parietal cell autoantibodies (PCA) in primary biliary cirrhosis: a putative marker for recurrence after orthotopic liver transplantation?. <i>Annals of Hepatology</i> , 2010, 9, 181-5.	1.5	2
148	A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2009, 16, 295-308.	16.8	345
149	A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2009, 16, 447.	16.8	1
150	Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. <i>Hepatology</i> , 2009, 50, 1638-1645.	7.3	108
151	Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. <i>Journal of Clinical Virology</i> , 2009, 46, 210-215.	3.1	83
152	Impaired TRAIL-dependent cytotoxicity of CD1c-positive dendritic cells in chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2008, 15, 200-211.	2.0	20
153	Persistence of Occult Hepatitis B after Removal of the Hepatitis B Virus-Infected Liver. <i>Journal of Infectious Diseases</i> , 2008, 197, 355-360.	4.0	30
154	The Suppressive Effect That Myriocin Has on Hepatitis C Virus RNA Replication Is Independent of Inhibition of Serine Palmitoyl Transferase. <i>Journal of Infectious Diseases</i> , 2008, 198, 1091-1093.	4.0	6
155	Anti-HBc Seroconversion after Transplantation of Anti-HBc Positive Nonliver Organs to Anti-HBc Negative Recipients. <i>Transplantation</i> , 2006, 81, 808-809.	1.0	24
156	A Rare Cause of Nonalcoholic Fatty Liver Disease. <i>Annals of Internal Medicine</i> , 2006, 145, 154.	3.9	7
157	Correction: A Rare Cause of Nonalcoholic Fatty Liver Disease. <i>Annals of Internal Medicine</i> , 2006, 145, 396.	3.9	0
158	Effects of cyclosporine on human dendritic cell subsets. <i>Transplantation Proceedings</i> , 2005, 37, 20-24.	0.6	17
159	Living Repository of Millions of T and B Cell Receptor Sequences from Patients with COVID-19. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
160	Landscape of Public T Cell Receptors Associated with Recovery from COVID-19. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0